However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2‑fold elevation in median exposure (AUC and CThere were no differences in plasma concentrations of rosuvastatin between men and women.In a population pharmacokinetic analysis of two pediatric trials involving patients with heterozygous familial hypercholesterolemia 10 to 17 years of age and 8 to 17 years of age, respectively, rosuvastatin exposure appeared comparable to or lower than rosuvastatin exposure in adult patients.There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age ≥65 years).Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function.In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased.Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent.Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP). There was no detectable effect of Crestor on growth, weight, BMI (body mass index), or sexual maturation Crestor has not been studied in controlled clinical trials involving prepubertal patients or patients younger than 10 years of age with heterozygous familial hypercholesterolemia. Tell your doctor if you find it harder to control your blood sugar.Bersot TP. Select one or more newsletters to continue. All products displayed on 1mg are procured from verified and licensed pharmacies. Although the clinical significance of this finding is unknown, a dose reduction should be considered for patients on Crestor therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing.Increases in HbA1c and fasting serum glucose levels have been reported with HMG‑CoA reductase inhibitors, including Crestor. Similar findings have been seen with other drugs in this class.CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with several other members of this drug class. Please consult your doctor.If you miss a dose of Crestor 5mg Tablet, take it as soon as possible. Do not take two doses within 12 hours.For informational purposes only. The risk reduction for the primary end point was consistent across the following predefined subgroups: age, sex, race, smoking status, family history of premature CHD, body mass index, LDL‑C, HDL‑C, and hsCRP levels.The individual components of the primary end point are presented in Figure 3. Higher plasma concentrations of rosuvastatin have been reported in very small groups of patients (n=3 to 5) who have two reduced function alleles of the gene that encodes OATP1B1 (In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Inform your doctor if you have kidney disease, liver disease or diabetes before starting treatment with this medicine. Time to First Occurrence of Major Cardiovascular Events in JUPITERFigure 3. Generalized fatigue is more often in people with heart disease or those suffering from liver illness. Rosuvastatin is used together with diet to lower blood levels of "bad" cholesterol (low-density lipoprotein, or LDL), to increase levels of "good" cholesterol (high-density lipoprotein, or HDL), and to lower triglycerides (a type of fat in the blood). Use with Concomitant Therapy Patients taking cyclosporine and darolutamide The dose of CRESTOR should not exceed 5 mg once daily [see Warnings and Precautions (5.1), Drug Interactions (7.1), Drug Interactions (7.4) and Clinical Pharmacology (12.3)]. The most common adverse reactions that led to treatment discontinuation were:The most commonly reported adverse reactions (incidence ≥2%) in the Crestor controlled clinical trial database of 5394 patients were:Adverse reactions reported in ≥2% of patients in placebo-controlled clinical studies and at a rate greater than placebo are shown in Table 1. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \ 2C9, and Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%).After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route.A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among Caucasian, Hispanic, and Black or Afro-Caribbean groups.
It is used to lower cholesterol and to reduce the risk of heart disease. The dose of Crestor should not exceed 10 mg once daily Concomitant use of Crestor and regorafenib, the dose of Crestor should not exceed 10 mg once daily Patients taking atazanavir and ritonavir, lopinavir and ritonavir, simeprevir or combination of dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir and glecaprevir/pibrentasvirInitiate Crestor therapy with 5 mg once daily. Approved Uses for CRESTOR. how does are blood purifies.